Oscar Alcazar1, Luis F Hernandez1, Ernesto S Nakayasu2, Carrie D Nicora2, Charles Ansong2, Michael J Muehlbauer3, James R Bain3, Ciara J Myer4,5, Sanjoy K Bhattacharya4,5, Peter Buchwald1,6, Midhat H Abdulreda1,4,7,8. 1. Diabetes Research Institute, University of Miami Miller School of Medicine, Miami, FL 33136, USA. 2. Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99354, USA. 3. Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC 27701, USA. 4. Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA. 5. Miami Integrative Metabolomics Research Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA. 6. Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, USA. 7. Department of Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA. 8. Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Abstract
BACKGROUND: Biomarkers are crucial for detecting early type-1 diabetes (T1D) and preventing significant β-cell loss before the onset of clinical symptoms. Here, we present proof-of-concept studies to demonstrate the potential for identifying integrated biomarker signature(s) of T1D using parallel multi-omics. METHODS: Blood from human subjects at high risk for T1D (and healthy controls; n = 4 + 4) was subjected to parallel unlabeled proteomics, metabolomics, lipidomics, and transcriptomics. The integrated dataset was analyzed using Ingenuity Pathway Analysis (IPA) software for disturbances in the at-risk subjects compared to controls. RESULTS: The final quadra-omics dataset contained 2292 proteins, 328 miRNAs, 75 metabolites, and 41 lipids that were detected in all samples without exception. Disease/function enrichment analyses consistently indicated increased activation, proliferation, and migration of CD4 T-lymphocytes and macrophages. Integrated molecular network predictions highlighted central involvement and activation of NF-κB, TGF-β, VEGF, arachidonic acid, and arginase, and inhibition of miRNA Let-7a-5p. IPA-predicted candidate biomarkers were used to construct a putative integrated signature containing several miRNAs and metabolite/lipid features in the at-risk subjects. CONCLUSIONS: Preliminary parallel quadra-omics provided a comprehensive picture of disturbances in high-risk T1D subjects and highlighted the potential for identifying associated integrated biomarker signatures. With further development and validation in larger cohorts, parallel multi-omics could ultimately facilitate the classification of T1D progressors from non-progressors.
BACKGROUND: Biomarkers are crucial for detecting early type-1 diabetes (T1D) and preventing significant β-cell loss before the onset of clinical symptoms. Here, we present proof-of-concept studies to demonstrate the potential for identifying integrated biomarker signature(s) of T1D using parallel multi-omics. METHODS: Blood from human subjects at high risk for T1D (and healthy controls; n = 4 + 4) was subjected to parallel unlabeled proteomics, metabolomics, lipidomics, and transcriptomics. The integrated dataset was analyzed using Ingenuity Pathway Analysis (IPA) software for disturbances in the at-risk subjects compared to controls. RESULTS: The final quadra-omics dataset contained 2292 proteins, 328 miRNAs, 75 metabolites, and 41 lipids that were detected in all samples without exception. Disease/function enrichment analyses consistently indicated increased activation, proliferation, and migration of CD4 T-lymphocytes and macrophages. Integrated molecular network predictions highlighted central involvement and activation of NF-κB, TGF-β, VEGF, arachidonic acid, and arginase, and inhibition of miRNA Let-7a-5p. IPA-predicted candidate biomarkers were used to construct a putative integrated signature containing several miRNAs and metabolite/lipid features in the at-risk subjects. CONCLUSIONS: Preliminary parallel quadra-omics provided a comprehensive picture of disturbances in high-risk T1D subjects and highlighted the potential for identifying associated integrated biomarker signatures. With further development and validation in larger cohorts, parallel multi-omics could ultimately facilitate the classification of T1D progressors from non-progressors.
Authors: Midhat H Abdulreda; R Damaris Molano; Gaetano Faleo; Maite Lopez-Cabezas; Alexander Shishido; Ulisse Ulissi; Carmen Fotino; Luis F Hernandez; Ashley Tschiggfrie; Virginia R Aldrich; Alejandro Tamayo-Garcia; Allison S Bayer; Camillo Ricordi; Alejandro Caicedo; Peter Buchwald; Antonello Pileggi; Per-Olof Berggren Journal: Diabetologia Date: 2019-05-14 Impact factor: 10.122
Authors: Maikel L Colli; Jessica L E Hill; Laura Marroquí; Jessica Chaffey; Reinaldo S Dos Santos; Pia Leete; Alexandra Coomans de Brachène; Flavia M M Paula; Anne Op de Beeck; Angela Castela; Lorella Marselli; Lars Krogvold; Knut Dahl-Jorgensen; Piero Marchetti; Noel G Morgan; Sarah J Richardson; Décio L Eizirik Journal: EBioMedicine Date: 2018-09-27 Impact factor: 8.143
Authors: Gerardo A Ceballos; Luis F Hernandez; Daniel Paredes; Luis R Betancourt; Midhat H Abdulreda Journal: PLoS One Date: 2020-11-05 Impact factor: 3.240
Authors: Muhammad Z Chauhan; Peyton A Rather; Sajida M Samarah; Abdelrahman M Elhusseiny; Ahmed B Sallam Journal: Cells Date: 2022-06-17 Impact factor: 7.666
Authors: Carmen Peña-Bautista; Lourdes Álvarez-Sánchez; Antonio José Cañada-Martínez; Miguel Baquero; Consuelo Cháfer-Pericás Journal: Biomedicines Date: 2021-12-02